Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
ENOV 
Enovis Corp (ENOV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/23/2025: ENOV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $47
1 Year Target Price $47
| 7 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -47.45% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.56B USD | Price to earnings Ratio - | 1Y Target Price 47 |
Price to earnings Ratio - | 1Y Target Price 47 | ||
Volume (30-day avg) 11 | Beta 1.65 | 52 Weeks Range 25.47 - 49.38 | Updated Date 12/23/2025 |
52 Weeks Range 25.47 - 49.38 | Updated Date 12/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -24.36 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -61.22% | Operating Margin (TTM) 1.65% |
Management Effectiveness
Return on Assets (TTM) 0.97% | Return on Equity (TTM) -51.02% |
Valuation
Trailing PE - | Forward PE 7.55 | Enterprise Value 2963193163 | Price to Sales(TTM) 0.7 |
Enterprise Value 2963193163 | Price to Sales(TTM) 0.7 | ||
Enterprise Value to Revenue 1.33 | Enterprise Value to EBITDA 22.42 | Shares Outstanding 57189381 | Shares Floating 56435053 |
Shares Outstanding 57189381 | Shares Floating 56435053 | ||
Percent Insiders 1.57 | Percent Institutions 117.37 |
Upturn AI SWOT
Enovis Corp
Company Overview
History and Background
Enovis Corporation, formerly Colfax Corporation, was rebranded in March 2022. The company was founded in 1931 and has undergone significant transformations, including acquisitions and divestitures, to focus on medical technologies. Its evolution reflects a strategic shift towards specialized healthcare solutions.
Core Business Areas
- Orthopaedics: Enovis's Orthopaedics segment focuses on developing and marketing a comprehensive portfolio of innovative solutions for the prevention, diagnosis, and treatment of orthopedic conditions. This includes implants, instruments, and related technologies for joint reconstruction, trauma, and sports medicine.
- Rehabilitation: The Rehabilitation segment offers a broad range of products and services designed to help patients recover from injuries, surgery, or chronic conditions. This includes bracing and supports, physical therapy equipment, electrotherapy devices, and digital health solutions for remote patient monitoring.
Leadership and Structure
Enovis is led by a seasoned executive team. While specific names and detailed organizational charts are dynamic, the structure typically includes a CEO, CFO, and heads of key business units and functional areas like R&D, sales, and operations. The company operates with a divisional structure aligned with its core business areas.
Top Products and Market Share
Key Offerings
- Distinctu00ae Shoulder System: A highly integrated shoulder arthroplasty system designed for anatomical restoration and reproducible outcomes. Market share data for specific product lines is proprietary, but it competes within the significant shoulder arthroplasty market against companies like Stryker and Zimmer Biomet.
- LifeModu00ae Hip System: A comprehensive hip arthroplasty system offering a range of implants and instruments for primary and revision hip replacement surgery. Competitors include major players in the hip implant market such as Johnson & Johnson (DePuy Synthes) and Smith+Nephew.
- Exosu00ae Bracing Solutions: A line of off-the-shelf and custom-fit braces for various musculoskeletal conditions, including osteoarthritis and sports injuries. This segment competes with companies like DonJoy (part of DJO Global) and Ossur.
- Chattanoogau00ae Rehabilitation Equipment: A broad range of electrotherapy, ultrasound, and exercise equipment used in physical therapy clinics and rehabilitation centers. Competitors include Mettler Electronics and Dynatronics.
Market Dynamics
Industry Overview
The medical device industry, particularly in orthopaedics and rehabilitation, is characterized by innovation, consolidation, and increasing demand driven by an aging global population, rising rates of chronic diseases, and advancements in medical technology. The sector is highly regulated.
Positioning
Enovis is positioned as a focused medical technology company with a strong emphasis on innovation and customer-centric solutions in its chosen segments. Its competitive advantages lie in its specialized product portfolios, integrated approach to patient care (from prevention to rehabilitation), and a commitment to improving patient outcomes. The company aims to be a leader in specific niches within orthopaedics and rehabilitation.
Total Addressable Market (TAM)
The global orthopaedics market is estimated to be in the tens of billions of dollars, and the rehabilitation market is also substantial, running into billions. Enovis targets specific segments within these larger markets. Its positioning within the TAM is as a specialized provider of advanced solutions rather than a broad-based medical device conglomerate.
Upturn SWOT Analysis
Strengths
- Focused portfolio in high-growth medical technology segments (orthopaedics, rehabilitation).
- Strong brand recognition and established product lines.
- Commitment to innovation and R&D.
- Integrated solutions approach across treatment and recovery.
- Experienced leadership team.
Weaknesses
- Smaller market share compared to larger, diversified medical device giants.
- Reliance on a few key product lines.
- Potential challenges in scaling rapidly to meet global demand.
- Integration of acquired technologies and companies can be complex.
Opportunities
- Growing demand for joint replacement surgeries due to an aging population.
- Increasing adoption of digital health and remote patient monitoring in rehabilitation.
- Expansion into emerging markets.
- Strategic acquisitions to enhance product offerings and market reach.
- Further development of personalized medicine approaches in orthopaedics.
Threats
- Intense competition from larger and more established medical device companies.
- Regulatory changes and pricing pressures from healthcare payers.
- Economic downturns affecting healthcare spending.
- Technological disruption from new entrants or alternative treatments.
- Supply chain disruptions and raw material cost volatility.
Competitors and Market Share
Key Competitors
- Stryker Corporation (SYK)
- Zimmer Biomet Holdings, Inc. (ZBH)
- Johnson & Johnson (JNJ)
- Smith+Nephew plc (SNN)
Competitive Landscape
Enovis faces fierce competition from larger, well-established medical device companies that possess greater financial resources, broader product portfolios, and extensive global distribution networks. Enovis's competitive advantage lies in its specialization and agility within its chosen niches, focusing on innovative solutions and personalized customer service to gain market share. Its ability to integrate acquisitions and foster innovation will be critical.
Major Acquisitions
DJO Global's surgical business
- Year: 2021
- Acquisition Price (USD millions): 1130
- Strategic Rationale: Acquisition of DJO's surgical business significantly expanded Enovis's orthopaedics portfolio, particularly in joint reconstruction and trauma, and enhanced its market presence.
u00d6ssur's Hybrid Limb Solutions business
- Year: 2024
- Acquisition Price (USD millions): 105
- Strategic Rationale: This acquisition strengthens Enovis's offerings in the prosthetics and orthotics market, particularly in advanced prosthetic solutions.
Growth Trajectory and Initiatives
Historical Growth: Enovis has pursued a growth strategy that has involved both organic expansion of its existing businesses and strategic acquisitions. The transition from Colfax to Enovis itself signifies a strategic realignment to accelerate growth in its chosen medical technology areas. Revenue growth has been a key focus.
Future Projections: Analyst projections for Enovis typically focus on continued revenue growth driven by product innovation, market penetration, and potential future acquisitions. Earnings growth is expected to follow, contingent on effective cost management and integration of new ventures. Specific EPS and revenue growth estimates vary among analysts.
Recent Initiatives: Recent initiatives likely include the launch of new orthopedic implant systems, expansion of digital health solutions in rehabilitation, and the integration of acquired businesses to leverage synergies and expand market access. The rebranding to Enovis itself was a significant initiative to better reflect its focus on medical technology.
Summary
Enovis Corporation is a specialized medical technology company with a strong focus on orthopaedics and rehabilitation. Its recent rebranding and strategic acquisitions highlight a commitment to growth and innovation in these key healthcare segments. While facing competition from larger players, its focused approach and developing product pipeline position it for continued expansion, though navigating regulatory landscapes and market dynamics remains crucial for sustained success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Enovis Corporation SEC Filings (10-K, 10-Q)
- Company Investor Relations Website
- Reputable Financial Data Providers (e.g., Bloomberg, Refinitiv, Yahoo Finance)
- Industry Research Reports
Disclaimers:
This JSON output is generated based on publicly available information and AI analysis. Financial data, market share, and projections are subject to change and should be independently verified. This information is for informational purposes only and does not constitute financial advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enovis Corp
Exchange NYSE | Headquaters Wilmington, DE, United States | ||
IPO Launch date 2008-05-08 | CEO & Director Mr. Damien McDonald | ||
Sector Healthcare | Industry Medical Devices | Full time employees 7367 | Website https://www.enovis.com |
Full time employees 7367 | Website https://www.enovis.com | ||
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company's Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Its Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. It distributes its products through independent distributors and directly under the ESAB and DJO brands. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.